Summary Background In the CheckMate 9ER trial, patients with advanced renal cell
carcinoma who received first-line nivolumab plus cabozantinib had significantly better …

Abstract Treatment paradigm for metastatic clear cell renal cell carcinoma (mccRCC) has
changed dramatically over the recent decades. From cytokines, interleukin-2 and interferon …

Approximately 400,000 patients are diagnosed with kidney cancer annually worldwide,
leading to approximately 170,000 deaths. Renal cell carcinoma (RCC) accounts for more …

Background In the phase 3 KEYNOTE-426 (NCT02853331) trial, pembrolizumab+ axitinib
demonstrated improvement in overall survival, progression-free survival, and objective …

Simple Summary Genitourinary malignancies include cancers along the urinary tract and the
male reproductive tract, encompassing the adrenal glands, kidneys, bladder, prostate, and …

Systemic therapy for metastatic renal cell carcinoma has continuously evolved over the last
two decades. Significant improvements in overall survival and quality of life of patients with …

Background Since the approval of tyrosine kinase inhibitors, angiogenesis inhibitors and
immune checkpoint inhibitors, the treatment landscape for advanced renal cell carcinoma …

ABSTRACT Background The 2021 American Society of Clinical Oncology (ASCO)
Genitourinary Cancers Symposium represents an unmissable event for oncologists who …

Introduction: Kidney cancer, primarily renal cell carcinoma (RCC), ranks among the top 10
most common malignancies in the male population of Hong Kong. In 2019, members of two …

Immunotherapy is a vital component of the management of advanced/metastatic RCC.
Recently, ICIs modulating the PD-1/PD-L1 and CTLA-4 pathways have entered the …